Express Pharma

DRL announces launch of Raloxifene HCl Tablets in the US market

1

DRL’s tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000

Dr Reddy’s Laboratories has launched of Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets in the United States market, approved by the US Food & Drug Administration (US FDA).

The Evista brand and generic had US sales of approximately $265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health*

Dr Reddy’s Raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000.

EP News Bureau

Comments are closed.